Attachment Theory Research

Working with our partners, worldwide veterinary health company, Ceva Animal Health, we have been highlighting fascinating new research into the attachment theory between children and young people and their companion animals.

Many experts agree that companion animals can be beneficial to human wellbeing, and there is considerable anecdotal evidence to support this idea. High-quality, peer-reviewed science in this area is, however, largely lacking. This makes it difficult to develop effective evidence-based policies, best practices and guidelines for organisations and individuals working in the field of animal-assisted interventions.

Sound policies and guidance are vital to ensure animal-assisted interventions – ranging from fully-trained assistance animals to family pets – respect the well-being of both humans and animals, and

deliver maximum benefits. A sound evidence base is also crucial if public health agencies and other organisations are to be convinced to allocate scarce resources to animal-assisted interventions over other options.

As part of its ongoing support to the International Association of Human-Animal Interaction Organizations (IAHAIO), Ceva is continuing to support innovative research to help enhance the science around the human-animal bond. It particularly focuses on how pets can improve the wellbeing of children and young people, including those living with mental health challenges. Earlier support from Ceva helped to shed light on a mechanism (synchrony 1) that may underlie the effect of dog-assisted therapy and how this makes a difference for children with autism spectrum disorder and Down syndrome 2.

The latest PhD researcher to be supported by Ceva is Danielle Groenewoud, an experienced clinical psychologist, who is comparing the nature of the bond between youngsters aged 8-14 years with their pets and also with their parents. In her clinical work with adolescents with depression or anxiety, Danielle is used to working with the whole family – parents and siblings, and often pets too. She realised, however, that 20-years ago, when she trained, there was nothing in the curriculum about the human animal bond and, even now, this topic receives only scant coverage.


Company News Videos

Our New York Stock Exchange-quoted client, Volition RX, has mastered the art of making company announcements…using video.

You can see a prime example of a key announcement from Volition Veterinary by clicking here.

Heska’s Nu.Q® Canine Cancer Screen and Monitor Test will operate on Heska’s proprietary Element i+® Immunodiagnostic Analyzer, a point-of-care platform which provides veterinarians with rapid, accurate, low cost, and easy-to-use on-site testing in the veterinary clinic, to support clinical decision-making and improve patient outcomes.

Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, said:
“This is a breakthrough moment for Volition: it is the first time the Nu.Q® platform is available outside of centralised laboratory testing. Our mission at Volition is to ensure that our Nucleosomics™ technology is accessible and affordable worldwide, to detect and monitor disease earlier and improve outcomes. We are delighted to be working with Heska and their remarkable point-of-care technology to enable vets, pets, and pet families to benefit from our innovative technology. We are thrilled to advance towards full commercial launch and license payment milestones.”

Kevin Wilson, Heska’s Chief Executive Officer and President said, “We are pleased now to offer our transformative Nu.Q® Canine Cancer Screen and Monitor Test at the point-of-care, which we believe will revolutionize canine cancer patient management. Available now for pre-order, the screen and monitoring test will assist veterinarians to detect cancer early, in the clinic, in minutes, and for under $50, to support clinical decision-making during annual check-ups, regular wellness exams, healthcare interventions, treatment cycles, and remission. While we also offer this technology at the central reference lab, we believe the benefits of point-of-care cancer screening and monitoring are significant and will provide outsized benefits to veterinarians, nursing and technical teams, pets, and pet families.”

“With this forthcoming launch, millions of pets will have access to critical cancer screening and monitoring in the clinic, to catch, treat and drive recovery from cancers earlier, for better healthcare outcomes and peace of mind. We believe that this innovation will be transformative to veterinarian healthcare as Heska begins to roll it out exclusively to the point-of-care, with our global commercial launch targeted for early in the second quarter of this year,” concluded Mr. Wilson.

Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals. For more information about Volition’s Nu.Q® technology go to: